Souders Financial Advisors Buys 37 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Souders Financial Advisors raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.6% in the 2nd quarter, Holdings Channel reports. The firm owned 1,436 shares of the pharmaceutical company’s stock after purchasing an additional 37 shares during the quarter. Souders Financial Advisors’ holdings in Vertex Pharmaceuticals were worth $673,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. University of Texas Texas AM Investment Managment Co. bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth about $25,000. Annapolis Financial Services LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth about $27,000. ICA Group Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth about $28,000. GHP Investment Advisors Inc. bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth about $29,000. Finally, Stephens Consulting LLC bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth about $31,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $465.08 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12 month low of $341.85 and a 12 month high of $510.64. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $479.30 and a 200 day moving average price of $454.54. The stock has a market cap of $120.04 billion, a PE ratio of 30.18 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. Vertex Pharmaceuticals’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period last year, the firm earned $3.53 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Guggenheim boosted their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Canaccord Genuity Group boosted their target price on Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a research report on Wednesday, July 31st. TD Cowen boosted their target price on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, August 2nd. Finally, Barclays downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $472.00 to $509.00 in a research note on Monday, August 5th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $487.23.

Insider Activity

In related news, Director Sangeeta N. Bhatia sold 646 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the transaction, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Sangeeta N. Bhatia sold 646 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now directly owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $487.34, for a total transaction of $1,111,135.20. Following the completion of the sale, the chief marketing officer now directly owns 27,819 shares in the company, valued at $13,557,311.46. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,767 shares of company stock worth $15,768,284. 0.20% of the stock is currently owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.